<DOC>
	<DOC>NCT00475215</DOC>
	<brief_summary>The purpose of the trial is to research the safety and to show faster recovery after administration of 2.0 mg/kg or 4.0 mg/kg Org 25969 (sugammadex) given as a reversal agent for ZemuronÂ® in subjects diagnosed with or having a history of pulmonary disease.</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of Org 25969 in Subjects With or Having a Past History of Pulmonary Disease (19.4.308)(P05932)</brief_title>
	<detailed_description />
	<criteria>ASA Class 2 to 3; 18 years of age or older; Diagnosed with or having a past history of pulmonary disease; Scheduled for elective surgical procedure under general anesthesia requiring neuromuscular block with the use of rocuronium; Scheduled for surgery in supine position; Given written informed consent; Subjects in whom a difficult intubation is expected due to anatomical malformations; Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction; Subjects known or suspected to have a (family) history of malignant hyperthermia; Subjects known or suspected to have an allergy to narcotics, muscle relaxants or other medications used during surgery; Subjects receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and Mg2+; Female subjects who are pregnant or breastfeeding; Females subjects of childbearing potential not using an acceptable method of birth control [condom or diaphragm with spermicide, vasectomized partner (&gt; 6 months), IUD, abstinence] or using only hormonal contraception as birth control; Subjects who had already participated in a Org 25969 trial including Protocol 19.4.308; Subjects who had participated in another clinical trial, not preapproved by Organon, within 30 days of entering into Protocol 19.4.308.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>